Article

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics

2021-06-16

Abstract excerpt

Polo-like kinase (PLK) family members play important roles in cell cycle regulation. The founding member PLK1 is oncogenic and preclinically validated as a cancer therapeutic target. Paradoxically, PLK2 (chromosome 5q11.2) is frequently deleted in human breast cancers, preferentially in basal-like and triple-negative breast cancer subtypes. Here, we found that PLK2 was tumor suppressive in breast cancer and knockd...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1477371d-893f-59d0-a488-9dad13387f28
DOI: 10.1101/2021.06.16.448722

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeuticsDOI 10.1101/2021.06.16.448722Read

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read

Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancersSemantic proximity Read

A review of Plks: Thinking outside the (polo) boxSemantic proximity Read

The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?Semantic proximity Read

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implicationsSemantic proximity Read

Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian CancerSemantic proximity Read

The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor MetastasisSemantic proximity Read

PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomasSemantic proximity Read

NONO directs PKM2-mediated H3T11ph to promote triple-negative breast cancer metastasis by activating SERPINE1 expressionSemantic proximity Read

Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cellsSemantic proximity Read

Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast CancerSemantic proximity Read

Polo-like kinase 2 targeting as novel strategy to sensitize mutant p53-expressing tumor cells to anticancer treatments.Semantic proximity Read